Opendata, web and dolomites


NORATEST: An e-Health solution for a better Alzheimer's diagnosis and management

Total Cost €


EC-Contrib. €






 NORATEST project word cloud

Explore the words cloud of the NORATEST project. It provides you a very rough idea of what is the project "NORATEST" about.

revenue    annual    lack    noratest    suffering    almost       hire    discriminate    diagnosis    combination    54m    people    platform    online    algorithm    innovative    shows    company    leaders    alzheimer    data    healthy    business    alzohis    health    tests    detection    accounting    5m    accumulate    pay    accurate    computer    dementia    signatures    2016    competitive    detectable    2026    worth    prototype    efficiency    disease    smart    32m    2050    sales    model    advantages    issue    detecting    worldwide    usa    trl6    cagr    efficient    earn    adaptable    reference    ad    coupled    diagnostic    blood    solution    stages    first    market    scalable    2030    analytics    direct    privacy    molecular    markets    projected    total    patients       affordable    duplicating    roi    ddiagnosis    2024    ones    motivated    employees    speed    12    biomarkers    diagnoses    detect    diseases    improvements    care    profit    charging    producing    global    neurodegenerative    countries    anticipating    combined    17    80m    gt    invasive    360k    medical    fast   

Project "NORATEST" data sheet

The following table provides information about the project.


Organization address
city: PARIS
postcode: 91400
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country France [FR]
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-SMEInst-2018-2020-1
 Funding Scheme SME-1
 Starting year 2019
 Duration (year-month-day) from 2019-12-01   to  2020-03-31


Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    ALZOHIS FR (PARIS) coordinator 50˙000.00


 Project objective

Alzheimer's disease (AD) is a major medical problem and is currently an issue of global general interest as the total number of people with dementia is projected to reach ~80M in 2030 and almost duplicating this number by 2050. The lack of an efficient and affordable solution in the AD's health care sector has motivated our company Alzohis to develop NORATEST, a very unique and innovative e-Health platform producing significant improvements, in terms of speed efficiency, in the detection of neurodegenerative diseases. By means of a novel combination of biomarkers “signatures” detectable in the blood with a state-of-the-art computer algorithm NORATEST can discriminate patients suffering AD from those healthy ones, as well as detecting other neurodegenerative diseases. Our prototype, currently at TRL6, is the first reliable non-invasive molecular diagnostic method able to detect the disease in the very early stages, offering several competitive and innovative advantages such as: Cost-effective novel technology, fast, accurate, early ddiagnosis, data privacy coupled to smart analytics, user-friendly and highly scalable and adaptable platform. Our business model is a pay-per-use combined model of charging per analysis and direct online sales. The global AD market shows great opportunities for us since it was worth €2.5 B in 2016 and is set to reach €12.6 B by 2026 (CAGR of 17.5%). Worldwide we expect a market growth in both established and in developing countries, anticipating >5M annual AD's diagnoses in the two main markets leaders based in Europe (2.5-3.5M diagnoses/year) and USA (1.5-2.5M diagnoses/year) by 2024. Our company goal is to become the reference for AD's diagnosis in Europe. We estimated that in 5 years (end of Phase 2 project), we will accumulate 360K diagnosis tests sales (revenue €54M) accounting for ~2% of the EU and USA market. We expect to hire 40 new technical and sales employees and earn ~€32M profit, with a ROI of 6.5.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "NORATEST" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email ( and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "NORATEST" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)

MCBD (2019)


Read More  

SQP (2019)

Opening new markets for Single Quantum Photodetectors

Read More  

Genetta (2019)

Pole climbing solution to improve safety at work and to prevent fatal accidents in industrial climbing

Read More